Sep. 23, 2024
PURA VIDACOSTA RICAThey hate our freedom...."Every decent man is ashamed of the government he lives under." - H.L. Mencken"When I give food to the poor, they call me a saint. When I ask why the poor have no food, they call me a communist."- Dom Helda Camara"The whole problem with the world is that fools and fanatics are always so certain of themselves, but wiser people so full of doubts."- Bertrand Russell"Untouched by the breath of God, unrestricted by human conscience, both capitalism and socialism are repulsive."- Alexander Solzhenitsyn
Jiayi Pharmaceutical are exported all over the world and different industries with quality first. Our belief is to provide our customers with more and better high value-added products. Let's create a better future together.
With a new treatment option against schistosomiasis for preschool-aged children on the horizon, key stakeholders recently convened in Istanbul to discuss the challenges that lie ahead and the collaborative efforts needed to ensure country readiness for equitable access.
The consultation was organized by Uniting Efforts for Innovation, Access and Delivery a joint initiative of the United Nations Development Programme (UNDP)-led Access and Delivery Partnership (ADP), the Global Health Innovative Technology (GHIT) Fund and the Government of Japan.
Schistosomiasis, also known as Bilharzia, is a chronic parasitic disease caused by blood flukes belonging to the genus Schistosoma. It thrives in areas where freshwater snails serve as intermediate hosts. The disease is predominantly endemic in the African continent, where it poses a significant public health challenge. Children are highly susceptible to infection due to their frequent contact with contaminated water.
Beyond the immediate health consequences, such as anaemia, stunted growth and impaired cognitive development, the disease burden of schistosomiasis extends past childhood, with long-term effects into adulthood. It is one of the most devastating neglected tropical diseases (NTDs), both in terms of its health impact and the socioeconomic consequences.
Are you interested in learning more about Praziquantel Costa Rica? Contact us today to secure an expert consultation!
Despite their vulnerability to the disease, preschool-aged children have been largely excluded from accessing treatment due to a lack of age-appropriate formulation of praziquantel, the recommended treatment against schistosomiasis. Until the development of a paediatric form of praziquantel, this gap in treatment options has left an estimated 24 million 2-5 year old preschool-aged children in Africa at-risk of schistosomiasis.
To address this, over the past decade, the Pediatric Praziquantel Consortium an international public-private partnership financially supported by the European and Developing Countries Clinical Trials Partnership and the GHIT Fund has focused its attention on the development of an innovative praziquantel paediatric treatment option for preschool-aged children, as well as an innovative access path to support translation of these R&D activities into impact. With the recent adoption of a positive scientific opinion on the new treatment by the European Medicines Agency, it is now in advanced stages, and countries where schistosomiasis is endemic are preparing for its possible introduction.
With the EMA positive opinion, the Consortium is delighted to see the efforts of the past 10 years become a reality, to be able to treat this vulnerable population and to contribute to the elimination of schistosomiasis as a public health challenge, said Dr. Béatrice Gréco, Director of Access, Merck Global Health Institute, representing the Consortium. This major milestone now opens the door to concrete conversations and actions in partnerships with endemic countries and all relevant parties to support wide adoption of this new product.
The availability of an efficacious and safe treatment formulation for preschool-aged children represents a critical tool in endemic countries arsenal against schistosomiasis, promising to improve the lives of millions of children and, by extension, the communities in which they live, said Dr. Hayato Urabe, Associate Vice President, Investment Strategy, Portfolio Development & Innovations at GHIT Fund. Equitable and sustainable access to this treatment will be essential to ensure that no child is left behind.
With this new product, we think that we are going to have an accelerated impact on the elimination of the disease towards the NTD roadmap targets, because all age groups at risk will be included in mass drug administration campaigns and also benefit from routine treatment in health facilities, said Dr. Amadou Garba Djirmay, Scientist, World Health Organization (WHO) Global Neglected Tropical Diseases Programme. There will be an improvement of the health of young children.
Contact us to discuss your requirements of Pigeon Praziquantel. Our experienced sales team can help you identify the options that best suit your needs.
Previous: None
Next: What is High-Quality Anti-Parasitic Bulk Drug and Why Do We Use Them?
If you are interested in sending in a Guest Blogger Submission,welcome to write for us!
All Comments ( 0 )